• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how weโ€™re building a company where people come first.

    Learn about our company

    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCEยฎ
    • BRINSUPRIยฎ
  • Responsibility

    Responsibility

    See how weโ€™re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility Report

    Our Responsibility Report reflects the culture and purpose we live by every day. We are committed to reporting annually on our progress and commitments.

    Learn more

  • Company
    • Company
    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships
  • Patients
    • Patients
    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCEยฎ
      BRINSUPRIยฎ
  • Responsibility
    • Responsibility
    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
    • Global Healthcare Compliance
    • Policies & Disclosures
  • Investors
  • Press Releases
  • Events & Presentations
  • Financials & Filings
    • Earnings Results
    • Annual Reports
    • SEC Filings
  • Corporate Governance
  • Responsibility Reports
  • Resources
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Email Alerts

SEC Filings

NASDAQINSM
YearTrailing 12-MonthsCalendar Year 2026Calendar Year 2025Calendar Year 2024Calendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013Calendar Year 2012Calendar Year 2011Calendar Year 2010Calendar Year 2009Calendar Year 2008Calendar Year 2007Calendar Year 2006Calendar Year 2005Calendar Year 2004Calendar Year 2003Calendar Year 2002Calendar Year 2001Calendar Year 2000
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Mergers & AcquisitionsProxy & Information StatementsOther
FormDescriptionDateFormat
CT ORDERConfidential treatment orderDec 23, 2014Open Confidential treatment order in HTML.Open Confidential treatment order in DOC file.Open Confidential treatment order in PDF file.Open Confidential treatment order in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsAug 11, 2014Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJul 31, 2014Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
CT ORDERConfidential treatment orderJun 30, 2014Open Confidential treatment order in HTML.Open Confidential treatment order in DOC file.Open Confidential treatment order in PDF file.Open Confidential treatment order in XLS file.
S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersMay 30, 2014Open Automatic shelf registration statement of securities of well-known seasoned issuers in HTML.Open Automatic shelf registration statement of securities of well-known seasoned issuers in DOC file.Open Automatic shelf registration statement of securities of well-known seasoned issuers in PDF file.Open Automatic shelf registration statement of securities of well-known seasoned issuers in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsApr 10, 2014Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2014Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 10, 2014Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJan 31, 2014Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJan 29, 2014Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
SC 13G/AAmendment to a previously filed SC 13GJan 10, 2014Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Sign Up

Investor Presentation

View the latest Insmed Investor Presentation

Download

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy Choices

ยฉ 2026 Insmed Incorporated. All Rights Reserved.

You are now leaving Insmed's website.

Insmed does not control, review, or endorse third-party websites, and you agree that Insmed is not responsible for the content of the website you are about to enter.